A Review on Metformin: Clinical Significance and Side Effects

Author(s):  
Mazumder Avijit ◽  
Singh Ashini

Metformin is a biguanide that has been used extensively worldwide for the treatment of type II diabetes mellitus. It improves glycaemic control by enhancing insulin sensitivity in liver and muscle. An advantage of metformin treatment is the tendency of weight reduction and the absence of significant hypoglycaemia; blood glucose levels are reduced only to normal as it does not stimulate insulin secretion. Metformin also has a beneficial effect on several cardiovascular risk factors including dyslipidemia, elevated plasminogen activator inhibitor 1 levels, other fibrinolytic abnormalities, hyperinsulinemia, and insulin resistance. Metformin enhances muscle and adipocyte insulin receptor number and/or affinity, increases insulin receptor tyrosine kinase activity, stimulates glucose transport and glycogen synthesis, and reduces both hepatic gluconeogenesis and glycogenolysis. The disadvantages are confined to the gastro-intestinal side effects and the potential risk of vitamin B 12 and folic acid deficiency during long-term use. These side effects can be minimized by slow titration and consumption with meals. The under lying mechanism for gastrointestinal intolerance are proposed to be stimulation of intestinal secretion of serotonin, alteration in incretin and metabolism of glucose, and malabsorption of bile salts. Lactic acidosis is rare contraindication associated with metformin. Most reported cases of lactic acidosis occur in patients with contraindications, particularly impaired renal function. Metformin has a good safety profile, efficacy and comparatively reduced cost. Its ability to improve insulin sensitivity and the cardiovascular risk profile of type II diabetic patients has enhanced its clinical use as first-line therapy.

2011 ◽  
Vol 30 (12) ◽  
pp. 1995-1997 ◽  
Author(s):  
Yasemin Usul Soyoral ◽  
Huseyin Begenik ◽  
Habib Emre ◽  
Enver Aytemiz ◽  
Mustafa Ozturk ◽  
...  

Metformin is an oral antidiabetic, which is frequently used in the treatment of type II diabetes mellitus. Serious side effects may be seen during the administration of high doses of metformin. Two cases of lactic acidosis due to ingestion of high dose metformin for suicidal purposes have been presented here; in both cases, clinical improvement was seen with bicarbonate hemodialysis.


2020 ◽  
Author(s):  
Mads Kjolby ◽  
Karen Marie Pedersen ◽  
Peter Breining ◽  
Niels Wellner ◽  
Karen Marie Juul Sørensen ◽  
...  

Type II diabetes mellitus (T2DM) has reached endemic levels and comprises a substantial burden to the patient and the society. Along with lifestyle factors, a number of genetic loci predisposing to T2DM have been suggested including SORCS1 that encodes a type-1 transmembrane receptor. Here we establish SorCS1 as a high-affinity binding partner for the insulin receptor (IR) that increases insulin affinity, Akt activation, and peripheral glucose uptake. Mice lacking full-length SorCS1 develop age-dependent insulin resistance characterized by increased plasma glucose and insulin levels and a blunted response to exogenous insulin. SorCS1 exists in three forms; as a transmembrane monomer and dimer, and as a truncated soluble form (sol-SorCS1) produced in adipose tissue and is present in plasma. Whereas dimeric SorCS1 engages the proform of the insulin receptor (proIR) during biosynthesis and supports its maturation, the monomeric form stabilizes the mature IR at the plasma membrane. In its soluble form, SorCS1 positively correlates with body mass index and inversely with plasma glucose in diabetic patients, and in mouse models of insulin resistance, overexpression or exogenous administration of the monomeric soluble receptor domain restores insulin sensitivity. We conclude that SorCS1 is a critical regulator of peripheral insulin sensitivity operating in both a cell autonomous and endocrine manner, and we propose sol-SorCS1 as a novel adipokine.


2021 ◽  
Vol 8 (6) ◽  
pp. 271-276
Author(s):  
Chinju Jose ◽  
Abhishek Pradhan ◽  
A. R Shabaraya

Increased drug related problems in diabetic patients treated with combinations of high doses of sulfonylureas and metformin was recently reported. This review article is aimed towards the assessment of drug related problems in patients treated with low-doses of sulfonylureas and biguanides. Sulphonylureas the second most commonly used antidiabetic drugs after metformin; there have been concerns regarding the cardiovascular safety of sulfonylureas. These safety concerns initiated with the University Group Diabetes Program conducted in the 1960s, found a sulfonylurea, tolbutamide, where tolbutamide is a first-generation sulfonylurea and was associated with an increased risk of all-cause and cardiovascular problems compared with placebo. Indeed, sulfonylureas have been associated with known cardiovascular risk factors like weight gain, fluid retention, and hypoglycemia. Phenformin, a biguanide, was related to lactic acidosis and withdrawn from use after causing increased risk factors within the University Group Diabetes Program since then, a more modern biguanide, metformin, has risen to its current place because the leading oral therapy for diabetes supported its relative lack of hazard from lactic acidosis and evidence especially from a subgroup of participants in the UK Prospective Diabetes Study, that it can reduce cardiovascular risk and other drug related problems. But there are certain studies showing that combination treatment with metformin and sulfonylurea is more effective, than drugs alone in enabling glycemic control in type 2 diabetes. However, safety of such combinations deserves further investigation. Keywords: Type2 diabetes mellitus, T2DM, drug related problems, sulfonylureas, biguanides.


2003 ◽  
Vol 88 (1) ◽  
pp. 317-322 ◽  
Author(s):  
Rossella D’Alfonso ◽  
Maria Adelaide Marini ◽  
Lucia Frittitta ◽  
Roberto Sorge ◽  
Simona Frontoni ◽  
...  

We investigated the significance of Gly1057Asp and Leu647Val insulin receptor substrate (IRS)-2 polymorphisms in two Italian cohorts comprising 186 glucose-tolerant subjects and 240 subjects with type 2 diabetes from the Lazio region (i.e. representative of central Italy), and 123 glucose-tolerant subjects from the Sicily region (i.e. representative of south Italy). The allelic frequency of Gly1057Asp variant did not differ between diabetics (32.9%) and nondiabetic subjects, whatever their ethnicity was (35.8% and 33.7% from Lazio and Sicily, respectively). As compared with Gly/Gly subjects within each group, Asp/Asp individuals showed no differences in quantitative traits, including fasting insulin and C-peptide, and several indices of insulin sensitivity and secretion. Only one of the diabetic patients was heterozygous for the Leu647Val variant, and none of the control subjects carried this variant. This patient had three children who were also heterozygous for this variant. They were glucose tolerant, and their insulin sensitivity and insulin secretion indices were within the range of age-matched controls. We also analyzed IRS-2 function in fibroblasts from carriers of Gly1057Asp or Leu647Val variant. No defects in IRS-2 expression, insulin-stimulated phosphorylation, or binding to the p85 subunit of phosphatidylinositol 3-kinase were observed. These results strongly argue against a major role of IRS-2 polymorphisms in the pathogenesis of type 2 diabetes.


Sign in / Sign up

Export Citation Format

Share Document